SuperworthArtiva Biotherapeutics price to book ratio ARTV
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 0.9×
- Peer median
- 5.0×
Artiva Biotherapeutics' price to book ratio is 0.9× as of Oct 23, 2026.
The median for 4 biotech stocks of a similar size is 5.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.9× | 0.7× | 3.1× |
| 2025 | 0.8× | 0.2× | 1.3× |
| 2024 | 1.3× | 1.2× | 1.5× |
Against its peers
Companies in Biotechnology nearest Artiva Biotherapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| ARTVArtiva Biotherapeutics | 0.9× |
| PLXProtalix BioTherapeutics | 2.9× |
| MGTXMeiraGTx | 4.1× |
| VCELVericel | 5.9× |
| ADMAAdma Biologics | 5.9× |
| Peer median | 5.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Artiva Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.